Singapore markets close in 3 hours 24 minutes
Straits Times Index
3,308.50 +8.50 (+0.26%) Nikkei
38,638.52 +5.50 (+0.01%) Hang Seng
18,024.84 -310.48 (-1.69%) FTSE 100
8,272.46 +67.35 (+0.82%) Bitcoin USD
64,569.55 -775.12 (-1.19%) CMC Crypto 200
1,352.19 -30.48 (-2.20%)
Cerevel Therapeutics Holdings, Inc. (CERE)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 41.85 |
| Open | 41.64 |
| Bid | 41.67 x 500 |
| Ask | 41.75 x 400 |
| Day's range | 41.48 - 41.90 |
| 52-week range | 19.59 - 43.59 |
| Volume | |
| Avg. volume | 1,133,351 |
| Market cap | 7.594B |
| Beta (5Y monthly) | 1.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
AbbVie acquiring Cerevel Therapeutics in $8.7B deal
AbbVie (ABBV) announced it is acquiring neuroscience drug developer Cerevel Therapeutics (CERE) for $45.00 per share, putting the deal value at about $8.7 billion. AbbVie Chairman and CEO Richard Gonzalez said in the announcement that the combined portfolios will present a "significant growth opportunity well into the next decade." The deal comes about a week after AbbVie announced it was acquiring cancer drugmaker ImmunoGen (IMGN) for just over $10 billion. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down the deal. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
© 2024 Yahoo. All rights reserved.